{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:47Z","timestamp":1791410807050,"version":"4.3.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dyslipidaemia is a common chronic kidney disease (CKD) and contributes to excessively elevated cardiovascular mortality. The pathophysiology is complex and modified by comorbidities like the presence\/absence of proteinuria, diabetes mellitus or drug treatment. This paper provides an overview of currently available treatment options. We focused on individuals with CKD and excluded those on renal replacement therapy (haemodialysis, peritoneal dialysis, or kidney transplantation). The use of statins is safe and recommended in most patients, but guidelines vary with respect to low-density lipoprotein (LDL) cholesterol goals. While no dedicated primary or secondary prevention studies are available for pro-protein convertase subtilisin\/kexin type 9 inhibitors, secondary analyses of large outcome trials reveal no effect modification on endpoints by the presence of CKD. Similar data have been shown for bempedoic acid, but no definite conclusion can be drawn with respect to efficacy and safety. No outcome trials are available for inclisiran while the cholesterol lowering effects seem to be unaffected by CKD. Finally, the value of fibrates and icosapent ethyl in CKD is unclear. Lipid abnormalities contribute to the massive cardiovascular disease burden in CKD. Lowering of LDL cholesterol with statins (and most likely PCSK9 inhibitors) reduces the event rate and thus statin therapy should be initiated in almost all individuals. Other interventions (bempedoic acid, inclisiran, fibrates, or icosapent ethyl) currently need a case-by-case decision before prescription.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvae058","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T22:05:19Z","timestamp":1723932319000},"page":"608-613","source":"Crossref","is-referenced-by-count":14,"title":["Management of dyslipidaemia in patients with comorbidities: facing the challenge"],"prefix":"10.1093","volume":"10","author":[{"given":"Gert","family":"Mayer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV (Nephrology and Hypertension) Medical University Innsbruck ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen , Essen ,","place":["Germany"]},{"name":"Department of Medicine and Research Center, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , Montr\u00e9al ,","place":["Canada"]},{"name":"Department of Integrative Physiology, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Molecular and Clinical Sciences Research Institute, St George's University of London , London SW17 0RE ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[{"name":"Preventive Cardio-Rheuma Clinic, Division of Research and Innovation, REMEDY Centre, Diakonhjemmet Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-3378","authenticated-orcid":false,"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Interventional Cardiology and Rhythmology, Clinic Ottakring , Vienna 1160 ,","place":["Austria"]},{"name":"Sigmund Freud University, Faculty of Medicine , Vienna 1020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-3297","authenticated-orcid":false,"given":"Andreas","family":"Zirlik","sequence":"additional","affiliation":[{"name":"University Heart Center Graz, Department Cardiology, Medical University Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Institute of Clinical Sciences, Karolinska Institute of Danderyd , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-9756","authenticated-orcid":false,"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[{"name":"Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) , Feldkirch ,","place":["Austria"]},{"name":"Private University in the Principality of Liechtenstein , Triesen ,","place":["Liechtenstein"]},{"name":"Vorarlberger Landeskrankenhausbetriebsgesellschaft , Feldkirch ,","place":["Austria"]},{"name":"Drexel University College of Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"2024110701232335300_bib1","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) lipid work group","year":"2013","journal-title":"Kidney Int"},{"key":"2024110701232335300_bib2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0272-6386(12)80030-8","article-title":"Lipoprotein metabolism and renal failure","volume":"21","author":"Attman","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"2024110701232335300_bib3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/life11040315","article-title":"Lipoprotein abnormalities in chronic kidney disease and renal transplantation","volume":"11","author":"Barbagallo","year":"2021","journal-title":"Life"},{"key":"2024110701232335300_bib4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","article-title":"Association between LDL\u2009-\u2009C and risk of myocardial infarction in CKD","volume":"24","author":"Tonelli","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2024110701232335300_bib5","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/ndt\/gfu022","article-title":"Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients","volume":"29","author":"Moradi","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2024110701232335300_bib6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11154-016-9402-z","article-title":"Dyslipidemia in patients with chronic kidney disease","volume":"18","author":"Hager","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"2024110701232335300_bib7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"2024110701232335300_bib8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Task Force Members:","year":"2019","journal-title":"Atherosclerosis"},{"key":"2024110701232335300_bib9","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2024110701232335300_bib10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7326\/0003-4819-157-4-201208210-00005","article-title":"Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Upadhyay","year":"2012","journal-title":"Ann Intern Med"},{"key":"2024110701232335300_bib11","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","article-title":"Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"34","author":"Hou","year":"2013","journal-title":"Eur Heart J"},{"key":"2024110701232335300_bib12","doi-asserted-by":"publisher","first-page":"CD007784","DOI":"10.1002\/14651858.CD007784.pub2","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"5","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2024110701232335300_bib13","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024110701232335300_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024110701232335300_bib15"},{"key":"2024110701232335300_bib16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jacl.2016.10.005","article-title":"Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: relationship with glomerular filtration rate and lipid metabolism","volume":"11","author":"Morena","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2024110701232335300_bib17","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"key":"2024110701232335300_bib18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.07.008","article-title":"Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: pooled analysis of nine ODYSSEY trials of alirocumab versus control","volume":"288","author":"Vallejo-Vaz","year":"2019","journal-title":"Atherosclerosis"},{"key":"2024110701232335300_bib19","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"FOURIER Steering committee and investigators. Efficacy and safety of Evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024110701232335300_bib20","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"CLEAR outcomes investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2024110701232335300_bib21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of Inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2024110701232335300_bib22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"ORION-10 and ORION-11 investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2024110701232335300_bib23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Veterans' Affairs High-density lipoprotein Intervention Trial (VA-HIT) Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney Int"},{"key":"2024110701232335300_bib24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes. REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"2024110701232335300_bib25","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae058\/60420692\/pvae058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/7\/608\/60456901\/pvae058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/7\/608\/60456901\/pvae058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T20:25:03Z","timestamp":1730924703000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/7\/608\/7735334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,8,17]]},"published-print":{"date-parts":[[2024,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae058","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,8,17]]}}}